On February 28, The Alzheimer’s Drug Discovery Foundation, Beyond Batten Disease Foundation, and the National Multiple Sclerosis Society announced their funding collaboration to aid in the development of the Collaborative CNS Screening Initiative (CCSI), “a central repository of chemical compounds that have shown significant central nervous system activity.” The development

As people with primary progressive multiple sclerosis (PPMS) know, this form of MS seems to be left out of the research/treatment spotlight. However, an active recruitment for PPMS patients is being sponsored by Hoffmann-La Roche, according to the Clinical Trial.gov PPMS trial page. The trial documents and studies the efficacy